CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track

CytomX Therapeutics, Inc.

Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).
R&D expense $16.4M (-46% YoY); G&A $6.8M (-35% YoY); no net income or EPS disclosed.
CX-904 Phase 1a dose escalation data expected H1 2024; backfilling cohorts initiated Q4 2023.
CX-2051 IND filing by end of 2023; Phase 1 in solid tumors in 2024 with mCRC priority.
BMS-986288 Phase 2 ongoing; proof-of-concept data in MSS CRC and NSCLC expected in 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

CytomX Therapeutics, Inc. reported financial results for third quarter 2023.

Period: third quarter 2023
Result: reported results

Exact text from the filing

On November 7, 2023, CytomX Therapeutics, Inc., a Delaware corporation (the “Company”) issued a press release reporting its unaudited financial results as of and for the three and nine months ended September 30, 2023.

View on SEC.gov

Browse all earnings releases →

CytomX Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060221

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.